Poolbeg Pharma PLC

Poolbeg reported ending 2025 with GBP 7.7 million in cash and said it has financial runway into 2027. Management also said it raised GBP 4.865 million from the market during the year. No revenue, EPS, or gross margin figures were provided in the call. For guidance, the company expects POLB 001 interim CRS-prevention data in the summer of 2026, with patient recruitment and dosing to begin shortly after site initiation; the oral GLP-1 clinical trial is now expected to start in the second half of 2026 because of revised manufacturing lead times.

Jeremy Skillington framed the year as a major de-risking period for the company, emphasizing that Poolbeg is now in “execution mode” with POLB 001 and has built a strong partnering backdrop. He repeatedly pointed to the combination of regulatory progress, IP protection, payer interest, and a large unmet need as reasons he sees meaningful transaction potential. His tone was upbeat and persistent, but he stressed that the real value inflection point will be the upcoming clinical data.

No separate CFO remarks were included in the transcript. The financial commentary came from Jeremy Skillington, who said the company finished 2025 with GBP 7.7 million in cash, had raised GBP 4.865 million during the year, and believes the cash position supports operations into 2027. He tied that runway to the ability to reach multiple clinical milestones before needing to secure a partner-led transaction.

Analysts focused on the timing and sufficiency of the TOPICAL trial, asking whether summer 2026 means June, July, or August, whether the trial would trigger a clear go/no-go decision, and whether 30 patients is enough for a commercial outcome. Management said the exact summer timing depends on enrollment speed, but the open-label design should allow rapid readout, and 30 patients was described as ample for establishing effect size and informing later-stage trial design. They also said a positive interim readout could be enough for some potential partners to transact, while others may want more data or another study before moving ahead.